Treatment of Peritoneal Tuberculosis
Standard Treatment Regimen
- The European Respiratory Society recommends that peritoneal tuberculosis should be treated with the standard 6-month regimen used for pulmonary tuberculosis: 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol (2HRZE), followed by 4 months of isoniazid and rifampicin (4HR) 1, 2
- Administer four drugs daily: isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) during the initial intensive phase 1, 2
- Daily dosing is strongly recommended over intermittent dosing during the initial intensive phase 1
- Fixed-dose combinations of these drugs provide more convenient administration and may improve adherence 1
- Continue isoniazid and rifampicin for 4 additional months after completing the intensive phase 1, 2
- The continuation phase should only begin after confirming susceptibility to isoniazid and rifampicin 1
Evidence Supporting 6-Month Duration
- Non-respiratory tuberculosis, including peritoneal disease, responds to the same 6-month regimen as pulmonary TB 2
Treatment Monitoring and Adherence
- The European Respiratory Society recommends that directly observed therapy (DOT) is the central element of successful TB management and should be implemented whenever possible 1
- Patient-centered approaches should be individualized based on clinical and social history, using measures such as video-observed treatment, treatment supporters, and financial/social support 1
- Monitor for clinical improvement; patients not responding after 3 months require reevaluation 3
Special Situations
- If isoniazid resistance is detected: Use rifampicin, ethambutol, pyrazinamide, and a later-generation fluoroquinolone for 6 months 4, 5
- For multidrug-resistant TB (MDR-TB): Treatment must be based on drug susceptibility testing with consultation from a TB expert, using individualized regimens with at least 5 effective drugs 4
- The standard 6-month regimen is effective for HIV-positive patients with peritoneal TB 1